肾功能与心房颤动治疗不良反应风险的关联
该队列研究纳入115,564例新发心房颤动患者,评估基线eGFR分类与启动心率控制药、抗心律失常药、华法林、直接口服抗凝药或接受房颤操作后1年内不良反应风险的关联。结果显示较低eGFR与心率控制药和抗心律失常药不良反应风险升高相关,华法林大出血风险随eGFR降低呈梯度升高,而直接口服抗凝药未见此关联。
要点
- 较低eGFR与心率控制药不良反应风险升高相关,eGFR 15-29组HR 1.29。
- 华法林大出血风险随eGFR降低呈梯度升高,eGFR<15组HR 2.93。
- 直接口服抗凝药的大出血风险与eGFR无关联。
核心结论
- 较低eGFR与启动常用房颤治疗后不良反应风险显著升高相关,这些数据可能有助于房颤合并CKD患者的复杂治疗决策。
研究设计与样本
- 社区成人新发房颤后1年内新启动心率控制药、抗心律失常药、华法林、直接口服抗凝药或接受房颤操作的队列研究,共纳入115,564例患者。
- 基线eGFR采用门诊血清肌酐计算,不良反应通过生命体征数据库、心电图和行政编码确定。
- 采用Fine-Gray危险模型分析各eGFR分类与每种房颤治疗不良反应风险的关联。
主要发现
- 心率控制药不良反应(最常见低血压和心动过缓):与eGFR≥60 ml/min per 1.73 m2相比,eGFR 45-59组HR 1.14(95%CI 1.07-1.22),eGFR 30-44组HR 1.15(95%CI 1.06-1.25),eGFR 15-29组HR 1.29(95%CI 1.12-1.47)。
- 抗心律失常药不良反应(最常见QRS和QTc间期延长):与eGFR>60 ml/min per 1.73 m2相比,eGFR 45-59组HR 1.12(95%CI 1.01-1.23),eGFR<15组HR 1.43(95%CI 1.01-2.01)。
- 华法林大出血风险随eGFR降低呈梯度升高,eGFR<15 ml/min per 1.73 m2组HR 2.93(95%CI 1.99-4.30)。
- 接受直接口服抗凝药的患者中eGFR与大出血无关联。
- 房颤操作后1个月内不良反应发生率在合并CKD(n=18)和不合并CKD(n=41)的患者中均较低,进一步分析效力不足。
临床怎么用
- 原文未据此给出推荐。
局限性
- 房颤操作后1个月内不良反应在合并CKD(n=18)和不合并CKD(n=41)的患者中发生率均较低,进一步分析效力不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Atrial fibrillation (AF) is common in chronic kidney disease (CKD) and is treated with rate control medications, antiarrhythmic medications, as well as anticoagulation and procedures, each of which have associated risks. We aimed to evaluate the association of CKD status with the risks of adverse effects after initiation of AF therapies. METHODS: This was a cohort study of community-based adults who newly initiated rate control medications, antiarrhythmic medications, warfarin, direct oral anticoagulants (DOACs) or received AF procedures in the 1 year after diagnosis of AF. Baseline estimated glomerular filtration rate (eGFR) was calculated using outpatient serum creatinine measures. Adverse effects within 1 year related to each AF therapy or within 1 month of an AF procedure were ascertained from vital sign databases, electrocardiograms (ECGs), and administrative codes. Fine-Gray hazard models were used to study the association of eGFR categories with risk of adverse effects for each AF therapy. RESULTS: Among 115,564 patients with incident AF, lower eGFR (vs. eGFR ≥60 ml/min per 1.73 m2) was significantly associated with higher adjusted risk of adverse effects after initiation of rate control therapies (most commonly hypotension and bradycardia) as follows: eGFR 45-59 (hazard ratio [HR] 1.14, 95% confidence interval [CI] 1.07-1.22), 30-44 (HR 1.15, 95% CI 1.06-1.25), and 15-29 (HR 1.29, 95% CI: 1.12-1.47) ml/min per 1.73 m2. Lower eGFR was associated with higher adjusted risk of adverse effects (most commonly prolonged QRS and QTc intervals) after initiation of an antiarrhythmic medication (vs. eGFR >60 ml/min per 1.73 m2) as follows: eGFR 45-59 (HR 1.12, 95% CI 1.01-1.23) and eGFR<15 (HR 1.43, 95% CI 1.01-2.01) ml/min per 1.73 m2. CONCLUSION: There was a graded association between lower eGFR and risk of major bleeding with warfarin use, with the greatest risk among those with eGFR <15 ml/min per 1.73 m2 (HR of 2.93, 95% CI 1.99-4.30). There was no association of eGFR with major bleeding in patients receiving DOACs. Rates of adverse effects within 1 month of an AF procedure were low among patients with (n = 18) and without (n = 41) CKD and was underpowered for further analyses. In conclusion, lower eGFR was associated with significantly higher risks of adverse effects after initiation of commonly used therapies to treat AF. These data may help inform the complex therapeutic decisions in patients with CKD and AF.
引用
- Bansal N, Zelnick LR, An J, et al. Association of Kidney Function With Risk of Adverse Effects of Therapies for Atrial Fibrillation. Kidney Int Rep. 2022. PMID: 36938096. doi:10.1016/j.ekir.2022.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。